

**The Cutting Edge of Multiple Myeloma: The Evolving Role of CD38-directed Strategies**  
**How the Journey Might Change: Emerging Concepts, Future Directions and**  
**CD38-targeting Agents in MM**

**References**

1. Usmani SZ. The Year of the Bispecific. *The Hematologist*. 2024;21(1).  
<https://doi.org/10.1182/hem.V21.1.202415>
2. Mateos MV, Bahlis NJ, Costa LJ, et al. MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. *JCO*. 2022;40(16 suppl):TPS8072-TPS8072. DOI:10.1200/JCO.2022.40.16\_suppl.TPS8072
3. Dholaria BR, Weisel K, Mateos M-V, et al. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. *JCO*. 2023;41, 8003. DOI:10.1200/JCO.2023.41.16\_suppl.8003
4. Lancman G, Parsa K, Rodriguez C, et al. Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. *Blood*. 2022;140 (Supplement 1): 10073–10074. doi: <https://doi.org/10.1182/blood-2022-163733>
5. Lancman G, Sastow DL, Cho HJ, et al. Bispecific Antibodies in Multiple Myeloma: Present and Future. *Blood Cancer Discov*. 2021 Aug 17;2(5):423-433. doi: 10.1158/2643-3230.BCD-21-0028. PMID: 34661161; PMCID: PMC8510808.
6. Mateos MV, Bahlis NJ, Costa LJ, et al. MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. *JCO*. 2022;40(16 suppl):TPS8072-TPS8072. DOI:10.1200/JCO.2022.40.16\_suppl.TPS8072
7. Grosicki S, Crafoord J, Koh Y, et al. MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma. *JCO*. 2022;40(16 suppl):tps8074. <https://doi.org/10.13039/100004319>
8. Cohen YC, Moreau P, Tolbert J, et al. MonumentAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy. *Blood*. 2022;140 (Supplement 1): 4418–4419. doi: <https://doi.org/10.1182/blood-2022-162733>
9. Krishnan AY, Manier S, Terpos E, et al. MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant. *Blood*. 2022;140 (Supplement 1): 10148–10149. doi: <https://doi.org/10.1182/blood-2022-160173>

**The Cutting Edge of Multiple Myeloma: The Evolving Role of CD38-directed Strategies**  
**How the Journey Might Change: Emerging Concepts, Future Directions and**  
**CD38-targeting Agents in MM**

10. Manteca MVM, Grosicki S, Kim K, et al. MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma. *JCO*. 2023;41(16 suppl):TPS8066  
[https://doi.org/10.1200/JCO.2023.41.16\\_suppl.TPS806](https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS806)
11. Van Oekelen O, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. *Cancer Cell*. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29. PMID: 34242572; PMCID: PMC8238657.
12. Carlo-Stella C, Mazza R, Manier S, et al. RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study. *Blood*. 2022;140 (Supplement 1): 397–399. doi: <https://doi.org/10.1182/blood-2022-157988>
13. Lonial S, et al. Ixertin plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. *Lancet Haematol*. 2022 Nov;9(11):e822-e832.
14. Richardson PG, et al. Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial. *Blood*. 2022;140 (Supplement 1): 1366–1368.
15. Costacurta M, He J, Thompson PE, Shortt J. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy. *J Pers Med*. 2021 Nov 11;11(11):1185. doi: 10.3390/jpm11111185. PMID: 34834536; PMCID: PMC8623651.
16. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. *Blood*. 2010 Dec 16;116(25):5501-6. doi: 10.1182/blood-2010-07-298760. Epub 2010 Sep 7. PMID: 20823456; PMCID: PMC3031400.
17. Loree JM, Anand S, Dasari A, et al. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. *JAMA Oncol*. 2019 Oct 1;5(10):e191870. doi: 10.1001/jamaoncol.2019.1870. Epub 2019 Oct 10. PMID: 31415071; PMCID: PMC6696743.
18. Habr D, Corsaro M. Reimagining diversity in multiple myeloma clinical trials. *Hematol Oncol*. 2022 Oct;40(4):689-694.
19. Reich D, Nalls MA, Kao WH, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. *PLoS Genet*. 2009 Jan;5(1):e1000360. doi: 10.1371/journal.pgen.1000360. Epub 2009 Jan 30. PMID: 19180233; PMCID: PMC2628742.

**The Cutting Edge of Multiple Myeloma: The Evolving Role of CD38-directed Strategies**  
***How the Journey Might Change: Emerging Concepts, Future Directions and***  
***CD38-targeting Agents in MM***

20. Abdallah M, Arters F, Patel J, et al. When a Number Is Just a Number: Duffy-Null Blood Group Phenotype, Absolute Neutrophil Count, and Incidence of Neutropenic Fever and Chemotherapy Dose Reductions in Patients Treated for Plasma Cell Dyscrasias. *Blood*. 2023; 142 (Supplement 1): 7432. doi: <https://doi.org/10.1182/blood-2023-187811>
21. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. PMID: 38084760.
22. Krishnan A, Hoering A, Hari P, et al. Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC study): SWOG s1803. *Blood*. 2020; 136 (Supplement 1): 21–22. doi: <https://doi.org/10.1182/blood-2020-142913>
23. Attal M, Lauwers-Cances V, Hulin C, et al., for the IFM 2009 Study. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. *N Engl J Med*. 2017; 376:1311-1320 DOI: 10.1056/NEJMoa1611750
24. Shah N, Patel S, Pei H, et al. Subcutaneous Daratumumab (DARA SC) Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Minimal Residual Disease (MRD) Positive After Frontline Autologous Stem Cell Transplant (ASCT): The Phase 3 AURIGA Study. Poster presented at the 57<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology (ASCO); June 4 – 8, 2021.

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from sanofi-aventis US LLC